Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant

医学 内科学 布仑妥昔单抗维多汀 相伴的 挽救疗法 肿瘤科 淋巴瘤 移植 化疗 耐火材料(行星科学) 造血干细胞移植 血液学 外科 霍奇金淋巴瘤 天体生物学 物理
作者
Fulvia Fanelli,Stefan Hohaus,Maria Cantonetti,Giuseppe Cimino,Elsa Pennese,Roberta Battistini,Eugenio Galli,Raffaella Cerretti,Anna Proia,Federica Fatone,Ida Provenzano,Elisabetta Abruzzese,Erica Finolezzi,Alessandro Pulsoni,Luigi Rigacci
出处
期刊:Chemotherapy [Karger Publishers]
卷期号:68 (3): 131-137
标识
DOI:10.1159/000525819
摘要

Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory (R/R) to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors [CPI]) showed interesting results and were used as bridge therapies to allotransplant.The aim of this retrospective study in Lazio region was to evaluate the impact of these new therapies on outcome after allogeneic hematopoietic stem cell transplantation (allo-SCT) in comparison with standard chemotherapies used in the past.We selected all consecutive patients with diagnosis of HL transplanted in four hematology transplant units, and we collected data obtained from patients' records concerning all the treatments before allo-SCT.A total of 56 patients were enrolled in this study. All patients underwent allo-SCT for R/R HL. Seventeen patients (30%) received chemotherapy prior to allo-SCT (group B); they were treated between 2008 and 2015; and 39 patients (70%) received brentuximab vedotin (BV), CPI, or both before allo-SCT as a bridge to transplant (group A); they were treated between 2012 and 2020. Twenty-five patients were treated with BV alone, 2 with CPI alone, and 12 first with BV and then with CPI. No patient received concomitant BV and CPI. At 5 years from allo-SCT, overall survival (OS) was 59% and progression-free survival (PFS) was 65%. No statistical differences in OS or PFS were observed between patients in groups A and B. Relapse was significantly associated with a lower survival. The only factor associated with a reduced risk of relapse was development of any grade acute graft versus host disease (GVHD) (p > 0.02).This regional real-world experience shows the changes that have taken place in the last 10 years in R/R HL using new drugs to render a patient eligible for allo-SCT. This strategy appears to guarantee an impressive disease control with an increased risk of complications, for example, aGVHD, that appear to nullify this advantage at least in part.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
strack完成签到,获得积分10
1秒前
感动迎松发布了新的文献求助10
1秒前
1秒前
biubiubiu完成签到,获得积分10
1秒前
XHJ发布了新的文献求助10
1秒前
正直毛豆完成签到,获得积分10
1秒前
2秒前
2秒前
桐桐的应助被sjx采纳,获得10
2秒前
2秒前
shu发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
Maestro_S的应助被Mhh采纳,获得10
5秒前
12345678完成签到,获得积分10
5秒前
活力朋友发布了新的文献求助10
6秒前
niumochoubing发布了新的文献求助10
6秒前
6秒前
JinhuGuo发布了新的文献求助10
6秒前
天真的发布了新的文献求助10
6秒前
6秒前
1230完成签到,获得积分10
7秒前
zzzz完成签到 ,获得积分10
7秒前
芽芽发布了新的文献求助10
8秒前
zz发布了新的文献求助10
8秒前
8秒前
8秒前
11发布了新的文献求助10
8秒前
sunny发布了新的文献求助10
8秒前
1358201679完成签到,获得积分10
8秒前
科目三的应助被qin202569采纳,获得10
8秒前
天天快乐的应助被LeeNeaul采纳,获得30
9秒前
重要莹发布了新的文献求助10
9秒前
10秒前
希望天下0贩的0的应助被wldsd采纳,获得10
10秒前
yinyin发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182352
求助须知:如何正确求助?哪些是违规求助? 9571930
关于积分的说明 21820825
捐赠科研通 7778861
什么是DOI,文献DOI怎么找? 3433657
关于科研通互助平台的介绍 2557824
邀请新用户注册赠送积分活动 2479703